COMP <GO>
MRVI vs PVLA // RSI-14 & 200D SMA MOMENTUM
Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) VS. Palvella Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MRVI 2
— PVLA 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PVLA
LAST: $8.46 (-0.47%) • MKT CAP: $2.20B
rsi-technicals
53.6
LAST: $151.58 (+2.79%) • MKT CAP: $2.18B
rsi-technicals
59.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRVI VS. PVLA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRVI | PVLA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -27.90% | -7.10 | PVLA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.22% | -1.14% | -2.08 | PVLA | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -28.30% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.04 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | MRVI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 53.6 | 59.5 | -5.99 | PVLA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.20B | $2.18B | $12.8M | MRVI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRVI REV | PVLA REV | MRVI GROSS % | PVLA GROSS % | MRVI FCF | PVLA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $185.7M | $0 | 18.3% | — | -$70.7M | -$25.0M |
| FY 2024 | $259.2M | $0 | 41.8% | — | -$22.2M | -$10.8M |
| FY 2023 | $288.9M | $42.8M | — | — | $126.2M | -$13.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRVI // BETA —
PVLA // BETA —